Alpha Teknova, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
March 11, 2024 at 04:06 pm EDT
Share
Alpha Teknova, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 36.68 million compared to USD 41.42 million a year ago. Net loss was USD 36.78 million compared to USD 47.47 million a year ago.
Basic loss per share from continuing operations was USD 1.16 compared to USD 1.69 a year ago. Diluted loss per share from continuing operations was USD 1.16 compared to USD 1.69 a year ago.
Alpha Teknova, Inc. is a producer of critical reagents for the research, discovery, development, and commercialization of therapies, vaccines, and molecular diagnostics. It offers two primary business lines, which include lab essentials and clinical solutions. It also offers three primary product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. The Company offers its liquid cell culture media and supplements and molecular biology reagents in both of its two product categories; pre-poured media plates are available in its Lab Essentials category only. Its customers include pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions developing vaccines and therapies and performing basic research.